Characteristic | Patients, No. | Local control | Overall survival | |||
---|---|---|---|---|---|---|
Χ 2 | P | Χ 2 | P | |||
Gender | Male | 32 | 1.054 | 0.305 | 2.671 | 0.102 |
Female | 11 | |||||
Age | ≤70 | 23 | 0.832 | 0.362 | 0.116 | 0.733 |
>70 | 20 | |||||
Karnofsky performance status | 70 | 7 | 1.584 | 0.453 | 1.769 | 0.413 |
80 | 19 | |||||
90 | 17 | |||||
Comorbidities | Yes | 33 | 0.442 | 0.506 | 0.007 | 0.932 |
No | 10 | |||||
Type | Central | 8 | 0.427 | 0.514 | 0.173 | 0.678 |
Periphery | 35 | |||||
Histology | Squamous cell carcinoma | 17 | 0.696 | 0.874 | 0.975 | 0.807 |
Adenocarcinoma | 14 | |||||
Adenosquamouscarcinoma | 1 | |||||
Unspecified | 11 | |||||
Clinical stage | I | 23 | 14.888 | 0.000 | 7.926 | 0.005 |
II | 20 | |||||
Tumor size | ≤3 cm | 4 | 12.824 | 0.005* | 5.361 | 0.147 |
3-5 cm | 20 | |||||
5-7 cm | 10 | |||||
>7 cm | 9 | |||||
Dose/fraction (50% isodose line) | <6Gy | 27 | 1.337 | 0.248 | 0.979 | 0.322 |
≥6Gy | 16 | |||||
BED (50% isodose line) | <60Gy | 17 | 0.550 | 0.458 | 0.033 | 0.856 |
≥60Gy | 26 | |||||
Chemotherapy | no | 30 | 2.194 | 0.139 | 6.000 | 0.014 |
yes | 13 |